asset – Page 2 – Talk Bio

Actionable Insights Powered by AI

Amgen Discontinues Obesity Program, Shifts Focus to MariTide after Phase 1 Results

12 months ago talkbio0Tagged amgen, asset, Biotechnology, Clinical Trials, Drug Development, MariTide, Obesity, Phase 1 (qualifier value)

Amgen, obesity asset, phase 1 results, MariTide, drug development, biotechnology, clinical trials

Acorda Therapeutics Concludes $185M Asset Sale with Merz amid Bankruptcy Filing Following Disappointing Sales

1 year ago talkbio0Tagged Acorda, asset, Bankruptcy filing, Biogen returns, Declining sales, ex-US, Fampyra, Generic competition, Merz, Multiple Sclerosis drug, Neurological diseases, year

Acorda Therapeutics, $185M asset sale, Merz, Bankruptcy filing, Years of disappointing sales, Multiple Sclerosis drug Fampyra, Biogen returns ex-US rights, Generic competition, Declining sales, Neurological diseases